另一种用于治疗骨质疏松症的选择性雌激素受体调节剂。 - Suppr

Suppr

超能文献

Another selective estrogen-receptor modulator for osteoporosis.

作者信息

Becker Carolyn

出版信息

N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847.

DOI:10.1056/NEJMe0912847

PMID:20181977

Abstract

摘要

相似文献

Another selective estrogen-receptor modulator for osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847.

Lasofoxifene in postmenopausal women with osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692.

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2228; author reply 2228-9.

Tipping the balance for the primary prevention of breast cancer.

J Natl Cancer Inst. 2010 Nov 17;102(22):1683-5. doi: 10.1093/jnci/djq435. Epub 2010 Nov 4.

Third-generation SERMs may face uphill battle.

J Natl Cancer Inst. 2010 Nov 17;102(22):1690-2. doi: 10.1093/jnci/djq477. Epub 2010 Nov 8.

The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.

Menopause. 2011 Jan;18(1):6-7. doi: 10.1097/gme.0b013e318203a46b.

[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].

Clin Calcium. 2004 Oct;14(10):85-93.

[Evidence of raloxifene on postmenopausal osteoporosis].

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:374-80.

Not all SERMs are created equal.

Menopause. 2006 May-Jun;13(3):325-7. doi: 10.1097/01.gme.0000222332.31101.42.

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

J Natl Cancer Inst. 2010 Nov 17;102(22):1706-15. doi: 10.1093/jnci/djq415. Epub 2010 Nov 4.

引用本文的文献

Roles of estrogen in the formation of intracranial aneurysms in ovariectomized female mice.

Neurosurgery. 2014 Dec;75(6):690-5; discussion 695. doi: 10.1227/NEU.0000000000000528.

Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.

Curr Breast Cancer Rep. 2012 Sep 1;4(3):207-215. doi: 10.1007/s12609-012-0082-8.

Loss of androgen receptor promotes adipogenesis but suppresses osteogenesis in bone marrow stromal cells.

Stem Cell Res. 2013 Sep;11(2):938-50. doi: 10.1016/j.scr.2013.06.001. Epub 2013 Jun 10.

Aging and bone loss: new insights for the clinician.

Ther Adv Musculoskelet Dis. 2012 Apr;4(2):61-76. doi: 10.1177/1759720X11430858.

Innovative oral treatments of uterine leiomyoma.

Obstet Gynecol Int. 2012;2012:943635. doi: 10.1155/2012/943635. Epub 2012 Feb 16.

Medical treatment of uterine leiomyoma.

Reprod Sci. 2012 Apr;19(4):339-53. doi: 10.1177/1933719111432867. Epub 2012 Feb 28.

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.

Calcif Tissue Int. 2011 Aug;89(2):91-104. doi: 10.1007/s00223-011-9499-8. Epub 2011 Jun 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Another selective estrogen-receptor modulator for osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847.

Lasofoxifene in postmenopausal women with osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692.

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2228; author reply 2228-9.

Tipping the balance for the primary prevention of breast cancer.

J Natl Cancer Inst. 2010 Nov 17;102(22):1683-5. doi: 10.1093/jnci/djq435. Epub 2010 Nov 4.

Third-generation SERMs may face uphill battle.

J Natl Cancer Inst. 2010 Nov 17;102(22):1690-2. doi: 10.1093/jnci/djq477. Epub 2010 Nov 8.

The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.

Menopause. 2011 Jan;18(1):6-7. doi: 10.1097/gme.0b013e318203a46b.

[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].

Clin Calcium. 2004 Oct;14(10):85-93.

[Evidence of raloxifene on postmenopausal osteoporosis].

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:374-80.

Not all SERMs are created equal.

Menopause. 2006 May-Jun;13(3):325-7. doi: 10.1097/01.gme.0000222332.31101.42.

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

J Natl Cancer Inst. 2010 Nov 17;102(22):1706-15. doi: 10.1093/jnci/djq415. Epub 2010 Nov 4.

引用本文的文献

Roles of estrogen in the formation of intracranial aneurysms in ovariectomized female mice.

Neurosurgery. 2014 Dec;75(6):690-5; discussion 695. doi: 10.1227/NEU.0000000000000528.

Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.

Curr Breast Cancer Rep. 2012 Sep 1;4(3):207-215. doi: 10.1007/s12609-012-0082-8.

Loss of androgen receptor promotes adipogenesis but suppresses osteogenesis in bone marrow stromal cells.

Stem Cell Res. 2013 Sep;11(2):938-50. doi: 10.1016/j.scr.2013.06.001. Epub 2013 Jun 10.

Aging and bone loss: new insights for the clinician.

Ther Adv Musculoskelet Dis. 2012 Apr;4(2):61-76. doi: 10.1177/1759720X11430858.

Innovative oral treatments of uterine leiomyoma.

Obstet Gynecol Int. 2012;2012:943635. doi: 10.1155/2012/943635. Epub 2012 Feb 16.

Medical treatment of uterine leiomyoma.

Reprod Sci. 2012 Apr;19(4):339-53. doi: 10.1177/1933719111432867. Epub 2012 Feb 28.

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.

Calcif Tissue Int. 2011 Aug;89(2):91-104. doi: 10.1007/s00223-011-9499-8. Epub 2011 Jun 3.